Keyphrases
Activity Assay
24%
Binder
14%
Binding Mode
11%
Cancer Cells
24%
Chemical Space
16%
Cytokine Inhibitors
12%
Deregulation
13%
Drug Selectivity
24%
Erythropoietin
14%
Erythropoietin Receptor
24%
Evolutionarily Conserved
8%
Family Members
20%
Functional Characterization
24%
Gene Expression
24%
Gene number
8%
Granule Proteins
16%
High-throughput Screening
24%
Hypoxia
24%
Hypoxia-related Genes
24%
In Vitro Profiling
24%
Inhibitor Screening
24%
Isoform Selectivity
32%
JAK Inhibitors
40%
JAK2V617F
23%
Janus Kinase
24%
Janus Kinase 1 (JAK1)
10%
Janus Kinase 2 (JAK2)
100%
Janus Kinase Inhibitors
51%
Kinase Activity
15%
Kinase Regulation
24%
Knock-in Mouse Model
16%
Leukemia
24%
Liver
16%
MicroRNA
18%
MiR-1-3p
24%
MiR-96
16%
Myeloproliferative Neoplasms
31%
Navitoclax
24%
On Demand
8%
Pseudokinase Domain
31%
Rheumatic Diseases
24%
RNA Binding
24%
RNA-binding Protein
26%
Small Molecule Ligands
24%
Small Molecules
14%
SND1
32%
Structural Characterization
24%
Tudor-SN
24%
Tyrosine Kinase 2 (TYK2)
8%
X-ray Crystal Structure
11%
Biochemistry, Genetics and Molecular Biology
Adenosine Triphosphate
16%
Artificial Intelligence
24%
Biotin
8%
Body Size
8%
Cancer Cell
24%
Crystal Structure
6%
Cytokine
49%
Dimerization
5%
Drug Selectivity
24%
Enzyme
24%
Erythropoietin
8%
Erythropoietin Receptor
24%
Gene Deletion
8%
Gene Expression
24%
High Throughput Screening
24%
Isoform
28%
Janus Kinase
24%
Janus Kinase 1
8%
Janus Kinase 2
72%
Janus Kinase Inhibitor
40%
Kinase
41%
Knockout Mouse
16%
Mediator
8%
Messenger RNA
16%
MicroRNA
24%
Myeloid
8%
Organ Size
8%
Phosphotransferase
41%
Receptor Tyrosine Kinase
8%
RNA Binding
24%
RNA Splicing
8%
RNA-binding Protein
26%
Small Molecule
18%
SND1
32%
Stress Granule
8%
Suramin
7%
Transcription
24%
Tyrosine Kinase
8%
Upregulation
8%
X Ray
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adenosine Triphosphate
21%
Autoimmune Disease
13%
Binding Site
8%
Cytokine
59%
Drug Discovery
6%
Drug Selectivity
24%
Erythropoietin
12%
Fedratinib
8%
Hematologic Disease
8%
High-Throughput Screening
24%
Inflammatory Disease
8%
Janus Kinase
27%
Janus Kinase 1
32%
Janus Kinase 2
24%
Janus Kinase 2 Inhibitor
48%
Janus Kinase Inhibitor
51%
Leukemia
24%
Malignant Neoplasm
24%
microRNA
14%
microRNA 1
24%
Momelotinib
8%
Myeloproliferative Neoplasm
25%
Navitoclax
24%
Pacritinib
8%
Phosphotransferase
36%
Protein Tyrosine Kinase
8%
Rheumatic Disease
24%
Ruxolitinib
8%
Side Effect
8%
Suramin
14%
Tumor Suppressor Protein
9%
